ArticleOpen medicine (Warsaw, Poland)2026
Glucose-to-albumin ratio and mortality in ICU patients with acute pancreatitis.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Acute pancreatitis (AP) carries a high mortality risk in ICU patients. The glucose-to-albumin ratio (GAR), reflecting metabolic stress and albumin status, may serve as a simple prognostic marker. This study evaluated the association between GAR and mortality in ICU patients with AP. Methods: Data from 754 ICU patients with AP from the MIMIC-IV database were analyzed. Patients were divided into quartiles based on GAR. Multivariable Cox regression, Kaplan-Meier survival analysis, Boruta algorithm, and machine learning models were used to assess the relationship between GAR and 30-day and 90-day mortality. Results: Elevated GAR was independently associated with increased mortality risk. For 30-day mortality, GAR had the highest AUC (0.69) compared to albumin, SOFA, and glucose. Patients in the highest GAR quartile had a 10.2-fold increased risk of 30-day mortality (p<0.001). The Boruta algorithm identified GAR as an important predictor, and LightGBM showed the best performance (AUC=0.83). Conclusions: GAR was independently associated with 30-day and 90-day mortality in ICU patients with AP. As a simple and readily available biomarker, GAR may help improve early mortality risk stratification in this critically ill population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.